Study or Subgroup	ACE/ARB Mean	ACE/ARB SD	ACE/ARB Total	Placebo Mean	Placebo SD	Placebo Total	Weight	Mean difference IV, Random, 95% CI
2.4.1 ACE/ARB (< 1 Year)								
Agha A, 2009	-54.4	17.4	171	-0.8	22.2	190	10.7%	-53.60 [-57.69 , -49.51]
Dragović T 2003	-43.7	22.2	10	22.6	59.2	10	5.2%	-66.30 [-105.49 , -27.11]
Romero R 1993	-33	14.7	13	10	16.9	13	9.8%	-43.00 [-55.18 , -30.82]
Vongterapak S 1998	-1.8	20.4	16	8.4	17.6	12	9.5%	-10.20 [-24.31 , 3.91]
Zandbergen AA 2003	0	53.3	74	13.1	59.7	73	8.8%	-13.10 [-31.40 , 5.20]
Subtotal			**284**			**298**	**44.0%**	**-35.43 [-55.82 , -15.04]**
Test for overall effect: Z = 3.41 (P = 0.0007)								
Heterogeneity: Tau² = 452.38; Chi² = 50.19, df = 4 (P < 0.00001); I² = 92%								
2.4.2 ACE/ARB (1-3 Years)								
Bojestig M 2001 (a)	-15	220.1	19	-13	52	18	1.3%	-2.00 [-103.84 , 99.84]
Bojestig M 2001 (b)	12	306.1	18	-13	52	18	0.7%	25.00 [-118.43 , 168.43]
Crepaldi G 1998	-29	33.6	42	31	37.7	44	9.3%	-60.00 [-75.08 , -44.92]
Jerums G 2001	-37.78	2.83	13	30.53	5.29	10	10.8%	-68.31 [-71.93 , -64.69]
Laffel LM 1995	-26.29	28.8	67	21.78	59.4	70	9.3%	-48.07 [-63.60 , -32.54]
Subtotal			**159**			**160**	**31.3%**	**-58.71 [-71.73 , -45.69]**
Test for overall effect: Z = 8.84 (P < 0.00001)								
Heterogeneity: Tau² = 99.93; Chi² = 10.16, df = 4 (P = 0.04); I² = 61%								
2.4.3 ACE/ARB (> 3 Years)								
Ahmad 1997 (a)	-54	70.6	37	122	173.9	36	3.0%	-176.00 [-237.19 , -114.81]
Ahmad 1997 (b)	-35	47.3	52	32	75.6	51	7.6%	-67.00 [-91.41 , -42.59]
Makino, H 2008 (a)	-37	102.3	54	40	120.5	58	4.9%	-77.00 [-118.31 , -35.69]
Makino, H 2008 (b)	-56	93.1	51	40	120.5	58	5.0%	-96.00 [-136.18 , -55.82]
Ravid M 1993	-3	83.2	49	187	140.1	45	4.2%	-190.00 [-237.10 , -142.90]
Subtotal			**243**			**248**	**24.7%**	**-117.61 [-165.29 , -69.94]**
Test for overall effect: Z = 4.84 (P < 0.00001)								
Heterogeneity: Tau² = 2467.09; Chi² = 28.09, df = 4 (P < 0.0001); I² = 86%								
Total			**686**			**706**	**100.0%**	**-59.64 [-71.96 , -47.32]**

Test for overall effect: Z = 9.49 (P < 0.00001)
Test for subgroup differences: Chi² = 10.47, df = 2 (P = 0.005), I² = 80.9%
Heterogeneity: Tau² = 363.83; Chi² = 161.54, df = 14 (P < 0.00001); I² = 91%



Supplementary Figure 1: Reduction of moderately increased albuminuria (A2) based on duration of use of ACEIs/ARBs